Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease

Bibliography

• HANKEY GJ, EIKELBOOM JW: Homo cysteine and vascular disease. Lancet (1999) 354 (9176):407–413.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, LONN E, GENEST J, JR., HANKEY G, YUSUF S: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. (1999) 131 (5):363–375.
   PubMed Web of Science ®Google Scholar
• D'ANGELO A, SELHUB J: Homocysteine and thrombotic disease. Blood (1997) 90 (1) :1–11.
   PubMed Web of Science ®Google Scholar
• MUDD SH, FINKELSTEIN JD, REFSUM H et al.: Homocys-teine and its disulfide derivatives: A suggested consensus terminology. Arterioscler. Thromb. Vasc. Biol. (2000) 20(7):1704–1706.
   PubMed Web of Science ®Google Scholar
• MUDD SH, LEVY HL, SKOVBY F: Disorders of transsulfu-ration. In: The Metabolic and Molecular Bases of Inherited Disease (1). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), McGraw-Hill, Inc., New York, USA (1995) :1279–1327.
   Google Scholar
• ••Classical overview of metabolic pathways involved inhomocysteine conversion.
   Google Scholar
• FOWLER B: The folate cycle and disease in man. Kidney Int. (2001). (In Press).
   Google Scholar
• VAN GULDENER C, DONKER AJM, JAKOBS C, TEERLINK T, DE MEER K, STEHOUWER CD: No net renal extraction of homocysteine in fasting humans. Kidney Int. (1998) 54(1):166–169.
   PubMed Web of Science ®Google Scholar
• VAN GULDENER C, KULIK W, BERGER R et al.: Homocys-teine and methionine metabolism in ESRD: A stable isotope study. Kidney Int. (1999) 56(3):1064–1071.
   PubMed Web of Science ®Google Scholar
• HUSSEIN WI, GREEN R, JACOBSEN DW, FAIMAN C:Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann. Intern. Med. (1999) 131 (5):348–351.
   PubMed Web of Science ®Google Scholar
• NAGAI Y, TAKAMURA T, NOHARA E, YAMASHITA H, KOBAYASHI K: Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men [letter]. Diabetes Care (1999) 22(6):1004.
   PubMed Web of Science ®Google Scholar
• ROSENBLATT: Inherited disorders of folate transport, and metabolism. In: The Metabolic and Molecular Bases of Inherited Disease (1). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), McGraw-Hill, Inc., New York, USA (1995).
   Google Scholar
• MCCULLY KS, WILSON RB: Ho m o cys tein e theory of arteriosclerosis. Atherosclerosis (1975) 2 2 (2):215–227.
   Google Scholar
• FODINGER M, WAGNER OF, HORL WH, SUNDER-PLASSMANN G: Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int. (2001). (In Press).
   Google Scholar
• FODINGER M, BUCHMAYER H, SUNDER-PLASSMANN G: Molecular genetics of homocysteine metabolism. Miner. Electrolyte Metab. (1999) 25(4-6):269–278.
   PubMedGoogle Scholar
• FODINGER M, HORL WH, SUNDER-PLASSMANN G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. j Nephrol. (2000) 1 3 (1):20–33.
   Google Scholar
• ••In-depth review of all aspects of MTHFR.
   Google Scholar
• TSAI MY, BIGNELL M, YANG F, WELGE BG, GRAHAM KJ, HANSON NQ: Polygenic influence on plasma homocys-teine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis (2 0 0 0) 1 49 (1):131–137.
   Google Scholar
• FROSST P, BLOM HJ, MILOS R et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nature Genet. (1995) 10(0:111–113.
   PubMedGoogle Scholar
• WEISBERG I, TRAN P, CHRISTENSEN B, SIBANI S, ROZENR: A second genetic polymorphism in methylenetetra-hydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. (1998) 64 (3):169–172.
   PubMed Web of Science ®Google Scholar
• LECLERC D, CAMPEAU E, GOYETTE P et al.: Human methionine synthase: cDNA cloning and identification of mutations in patients of the cb1G complementation group of folate/cobalamin disorders. Hum. Mol. Genet. (1996) 5 (12) :1867–1874.
   PubMed Web of Science ®Google Scholar
• WILSON A, PLATT R, WU Q et al.: A common variant inmethionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol. Genet. Metab. (1999) 67(4):317–323.
   PubMed Web of Science ®Google Scholar
• WILSON A, LECLERC D, ROSENBLATT DS, GRAVEL RA: Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE comple-mentation group of disorders in folate/cobalamin metabolism. Hum. Mol. Genet. (1999) 8 (11):2009–2016.
   PubMed Web of Science ®Google Scholar
• VAN DER PUT NMJ, GABREELS F, STEVENS EMB et al.: A second common mutation in the methylenetetrahy-drofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. (1998) 62 (5):1044–1051.
   Google Scholar
• BRATTSTROM L, WILCKEN DE, OHRVIK J, BRUDIN L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circula-tion (1998) 9 8 (23):2520–2526.
   Google Scholar
• FOLSOM AR, NIETO FJ, MCGOVERN PG et al.: Prospectivestudy of coronary heart disease incidence in relation to fasting homocysteine, related genetic polymor-phisms and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation (1998) 98 (3) :204–210.
   Google Scholar
• REFSUM H, UELAND PM: Recent data are not in conflictwith homocysteine as a cardiovascular risk factor. Curr. Opin. Lipidol (1998) 9(6):533–539.
   PubMed Web of Science ®Google Scholar
• VIEL A, DALL'AGNESE L, SIMONE F et al.: LOSS of hetero-zygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas. Br. J Cancer (1997) 75(8):1105–1110.
   Google Scholar
• FODINGER M, MANNHALTER C, WOLFL G et al.: Mutation (677 C to 1) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney/M. (1997) 52 (2):517–523.
   PubMed Web of Science ®Google Scholar
• ••First of a series of papers showing the effect of MTHFR677TT on plasma tHcy concentrations of renal failure patients as compared with healthy individuals.
   Google Scholar
• FODINGER M, WOLFL G, FISCHER G et al.: Effect of MTHFR677C Ton plasma total homocysteine levels in renal graft recipients. Kidney Int. (1999) 55 (3):1072–1080.
   PubMed Web of Science ®Google Scholar
• VYCHYTIL A, FODINGER M, WOLFL G et al.: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int. (1998) 53(6):1775–1782.
   PubMed Web of Science ®Google Scholar
• KIMURA H, GEJYO F, SUZUKI S, MIYAZAKI R: The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. j Am. Soc. Nephrol. (2000) 11 (5):885–893.
   PubMed Web of Science ®Google Scholar
• DIERKES J, DOMROSE U, AMBROSCH A, BOSSELMANN HP, NEUMANN KH, LULEY C: Response of hyperhomo-cysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin. Nephrol. (1999) 51 (2):108–115.
   PubMed Web of Science ®Google Scholar
• FODINGER M, BUCHMAYER H, HEINZ G et al.: Effect of MTHFR1298A C and MTHFR677C Tgenotypes on total homocysteine, folate and vitamin B12 plasma concentrations in kidney graft recipients. j Am. Soc. Nephrol. (2000) 1 1 (101918–1925.
   Google Scholar
• FODINGER M, BUCHMAYER H, HEINZ G et al.: Associa-tion of two polymorphisms in MTHFR with total homocysteine plasma levels in dialysis patients. (2000). (Submitted).
   Google Scholar
• MALINOW MR, NIETO FJ, KRUGER WD et al.: The effectsof folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methyleneterahydrofolate reductase genotypes. Arterioscler. Thromb. Vasc. Biol. (1997) 17(6):1157–1162.
   PubMed Web of Science ®Google Scholar
• KRUGER WD, EVANS AA, WANG L et al: Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid. Mol. Genet. Metab. (2000) 70(1) :53–60.
   PubMed Web of Science ®Google Scholar
• HAUSER AC, HAGEN W, REHAK W et al.: Comparison of intravenous folinic acid with intravenous folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. A randomized, double blinded trial. (Submitted).
   Google Scholar
• ••First randomised controlled study that compared iv. folicacid with iv. folinic acid in haemodialysis patients.
   Google Scholar
• SUNDER-PLASSMANN G, FODINGER M, BUCHMAYER H et al: Effect of high dose folic acid therapy on hyperho-mocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study. J. Am. Soc. Nephrol (2000) 1 1 (6):1106–1116.
   Google Scholar
• AMERICAN SOCIETY OF HUMAN GENETICS/AMERICAN COLLEGE OF MEDICAL GENETICS TEST AND TRANSFER COMMITTEE WORKING GROUP: Measurement and use of total plasma homocysteine. Am]. Hum. Genet. (1998) 63 (5):1541–1543.
   PubMed Web of Science ®Google Scholar
• ••Straight forward recommendations for measurement of tHcyplasma levels.
   Google Scholar
• MALINOW MR, BOSTOM AG, KRAUSS RM: Homocyst(e)ine, diet and cardiovascular diseases. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation (1999) 99(0:178–182.
   Google Scholar
• •Critical comments on the association of tHcy plasma concentrations and cardiovascular disease. Includes screening and treatment recommendations.
   Google Scholar
• SNOW CF: laboratory diagnosis of vitamin B12 andfolate deficiency: a guide for the primary care physician. Arch. Int. Med. (1999) 159(12):1289–1298.
   PubMed Web of Science ®Google Scholar
• MOLLOY AM, MILLS JL, KIRKE PN, WHITEHEAD AS, WEIRDG, SCOTT JM: Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: differences between the radioassay and microbiological assays [letter]. Clin. Chem. (1998) 44 (1):186–188.
   PubMed Web of Science ®Google Scholar
• MOELBY L, RASMUSSEN K, RASMUSSEN HH: Serum methylmalonic acid in uraemia. Scand. J. Clin. Lab. Invest. (1992) 52(0351–354.
   PubMed Web of Science ®Google Scholar
• DIERKES J, DOMROSE U, AMBROSCH A et al: Supple-mentation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism (1999) 48 (5):631–635.
   PubMed Web of Science ®Google Scholar
• MOELBY L, RASMUSSEN K, RING T, NIELSEN G: Relation-ship between methylmalonic acid and cobalamin in uremia. Kidney Int. (2000) 57 (1):265–273.
   PubMed Web of Science ®Google Scholar
• FODINGER M, SUNDER-PLASSMANN G, WAGNER OF: Trends in molecular diagnosis. Wien. Klin. Wochenschr. (1999) 111(8):315–319.
   PubMedGoogle Scholar
• CHRISTEN WG, AJANI UA, GLYNN RJ, HENNEKENS CH:Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch. Intern. Med. (2000) 160(4):422–434.
   Web of Science ®Google Scholar
• ••Critical review of the tHcy story.
   Google Scholar
• DUDMAN NP: An alternative view of homocysteine. Lancet (1999) 354(9195):2072–2074.
   PubMed Web of Science ®Google Scholar
• ••A 'must' for everyone involved or interested in homocys-teine research.
   Google Scholar
• DEN HEUER M, KOSTER T, BLOM HJ et al: Hyperhomo-cysteinemia as a risk factor for deep-vein thrombosis. N Engl. J. Med. (1996) 334(12):759–762.
   PubMedGoogle Scholar
• EICHINGER S, STOMPFLEN A, HIRSCHL M et al.: Hyperho-mocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb. Haemost. (1 9 9 8) 80 (4):566–569.
   Google Scholar
• DEN HEUER M, ROSENDAAL FR, BLOM HJ, GERRITS WB,BOS GM: Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb. Haemost. (1998) 80 (6):874–877.
   PubMed Web of Science ®Google Scholar
• CHAUVEAU P, CHADEFAUX B, COUDE M et al.: Hyperho-mocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. (1993) 43 (Suppl. 41) :S72–S77.
   Google Scholar
• BACHMANN J, TEPEL M, RAIDT H et al.: Hyperhomocys-teinemia and the risk for vascular disease in hemodialysis patients. J Am. Soc. Nephrol. (1995) 6 (1):121–125.
   PubMedGoogle Scholar
• BOSTOM AG, SHEMIN D, LAPANE KL et al.: Folate statusis the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis (1996) 123 (1-2):193–202.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, SHEMIN D, VERHOEF P et al.: Elevatedfasting total plasma homocysteine levels and cardio-vascular disease outcomes in maintenance dialysis patients. A p ro sp ective study. Arterioscler. Thromb. Vasc. Biol. (1997) 17(10:2554–2558.
   PubMedGoogle Scholar
• ROBINSON K, GUPTA A, DENNIS V et al.: Hyperhomo-cysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation (1996) 94 (10:2743–2748.
   PubMedGoogle Scholar
• MOUSTAPHA A, NASO A, NAHLAWI M et al: Prospective study of hyperhomocysteinemia as an adverse cardio-vascular risk factor in end-stage renal disease [published erratum appears in Circulation 1998 Feb 24;97(7):711]. Circulation (1998) 97(2):138–141.
   PubMed Web of Science ®Google Scholar
• ••Important prospective study establishing elevated tHcyplasma concentrations as CVD risk marker in dialysis patients.
   Google Scholar
• MASSY ZA, CHADEFAUX-VEKEMANS B, CHEVALIER A etHyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipi-ents. Nephrol. Dial. Transplant. (1994) 9(8):1103–1108.
   PubMed Web of Science ®Google Scholar
• ARNADOTTIR M, HULTBERG B, VLADOV V, NILSSON-EHLE P, THYSELL H: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation (1996) 61 (3):509–512.
   PubMed Web of Science ®Google Scholar
• DUCLOUX D, MOTTE G, CHALLIER B, GIBEY R, CHALOPIN JM: Serum total homocysteine and cardio-vascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. j Am. Soc. Nephrol. (2000) 11(0:134–137.
   PubMedGoogle Scholar
• HAGEN W, FODINGER M, HEINZ G, BUCHMAYER H, HORL WH, SUNDER-PLASSMANN G: The effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. A prospective study. Kidney Int. (2001) . (In Press).
   Google Scholar
• HARPEL PC, CHANG VT, BORTH W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc. Natl. Acad. ScL USA (1992) 89:10193–10197.
   PubMed Web of Science ®Google Scholar
• ••Important in vitro study.
   Google Scholar
• YI P, MELNYK S, POGRIBNA M, POGRIBNY IP, HINE RJ, JAMES SJ: Increase in plasma homocysteine associated withparallelincreasesinplasmaS-adenosylhomocysteine and lymphocyte DNA hypomethylation. J. Biol. Chem. (2000) . (In Press).
   Google Scholar
• HULTBERG B, ANDERSSON A, ISAKSOON A: Hypometh-ylation as a cause of homocysteine-induced cell damage in human cell lines. Toxicology (2000) 147 (2):69–75.
   PubMedGoogle Scholar
• KHAJURIA A, HOUSTON DS: Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Mood(2000) 96(3):966–972.
   Google Scholar
• BOGER RH, BODE-BOGER SM, SYDOW K, HEISTAD DD, LENTZ SR: Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperho-mocyst(e)inemia or hypercholesterolemia. Arterio-scler. Thromb. Vasc. Biol. (2000) 20(6):1557–1564.
   PubMed Web of Science ®Google Scholar
• OUTINEN PA, SOOD SK, PFEIFER SI et al.: Homocysteine-induced endoplasmatic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood (1999) 94 (3) :959–967.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, CULLETON BF: Hyperhomocysteinemia in chronic renal disease. j Am. Soc. Nephrol (1999) 10 (4):891–900.
   PubMed Web of Science ®Google Scholar
• Homo cysteine lowering trialist's collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ (1998) 316(7135):894–898.
   Google Scholar
• VAN DER WIELEN RPJ, VAN HEEREVELD HAEM, DE GROOT CPGM, VAN STAVEREN WA: Nutritional status of elderly female nursing home residents; the effect of supplementation with a physiological dose of water-soluble vitamins. Eur. j Clin. Nutr. (1995) 49 (9):665–674.
   PubMed Web of Science ®Google Scholar
• SHIMAKAWA T, NIETO FJ, MALINOW MR, CHAMBLESS LE, SCHREINER PJ, SZKLO M: Vitamin intake: a possible determinant of plasma homocysteine among middle-aged adults. Ann. Epidemiol (1997) 7(4):285–293.
   PubMed Web of Science ®Google Scholar
• VERHOEF P, RIMM EB, HUNTER DJ et al.: A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among US men. J. Am. Coll. Cardiol. (1998) 32 (2):353–359.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, DUELL PB, HESS DL et al.: Reduction ofplasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Eng]. J. Med. (1998) 338(15):1009–1015.
   PubMed Web of Science ®Google Scholar
• JACQUES PF, SELHUB J, BOSTOM AG, WILSON PW, ROSENBERG IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Eng]. J. Med. (1999) 340(19):1449–1454.
   PubMed Web of Science ®Google Scholar
• PETERSON JC, SPENCE JD: Vitamins and progression ofatherosclerosis in hyper-homocyst(e)inaemia [letter]. Lancet (1998) 351 (9098):263.
   PubMed Web of Science ®Google Scholar
• VERMEULEN EGJ, STEHOUWER CDA, TVVISK JWR et al.: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet (2000) 355:517–522.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, GARBER C: Endpoints for homocysteine-lowering trials. Lancet (2000) 355 (9203):511–512.
   PubMed Web of Science ®Google Scholar
• NAPPO F, DE ROSA N, MARFELLA R et al: Impairment of endothelial functions by acute hyperhomocys-teinemia and reversal by antioxidant vitamins. JAMA (1999) 281 (22):2113–2118.
   PubMed Web of Science ®Google Scholar
• WILMINK HW, STROES ES, ERKELENS WD et al.: Influenceof folic acid on postprandial endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. (2000) 20(1):185–188.
   PubMed Web of Science ®Google Scholar
• WOO KS, CHOOK P, LOLIN YI, SANDERSON JE, METREWELI C, CELERMAJER DS: Folic acid improves arterial endothelial function in adults with hyperho-mocystein emia. J. Am. Coll. Cardiol. (1 9 9 9) 34 (7):2002–2006.
   Google Scholar
• BELLAMY MF, MCDOWELL IFW, RAMSEY MW, BROWNLEE M, NEWCOMBE RG, LEWIS MJ: Oral folate enhances endothelial function in hyp erhomocystein-aemic subjects. Eur. j Clin. Invest. (1999) 29(8):659–662.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, WEVER RMF, KASTELEIN JJP, VAN DAM T,KOOMANS HA, RABELINK TJ: 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation (1998) 97 (3):237–241.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, WEVER RMF, KASTELEIN JJP et al.: Effectsof oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A random-ized placebo-controlled trial. Circulation (1999) 100 (4):335–338.
   PubMed Web of Science ®Google Scholar
• DE VRIESE AS, VAN DE VOORDE J, BLOM HJ, VANHOUTTE PM, VERBEKE M, LAMEIRE NH: 5-Methyltetrahydrofolate restores the impaired renal vasodilator response attributed to endothelium derived hyperpolarizing factor in diabetic rats. (Submitted).
   Google Scholar
• MALINOW MR: Homocyst(e)ine, vitamins and geneticinteractions in vascular disease. Can. J. Cardiol. (1999) 15 (Suppl. B):31B–34B.
   Google Scholar
• BOSTOM AG, GOHH RY, BEAULIEU AJ et al: Treatment of hyperhomocysteinemia in renal transplant recipi-ents. A randomized, placebo-controlled trial. Ann. Intern. Med. (1997) 127 (12):1089–1092.
   PubMed Web of Science ®Google Scholar
• •Good study examining the effect of folic acid, vitamin B6 and vitamin B12 on tHcy levels in renal transplant patients.
   Google Scholar
• VAN DER GRIEND R, BIESMA DH, HAAS FJ et al: The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations. J Intern. Med. (2000) 248(3):223–229.
   PubMed Web of Science ®Google Scholar
• SCHINDLER K, ZAUNER C, BUCHMAYER H et al: High prevalence of hyperhomocysteinemia in critically ill patients. Grit. Care Med. (2000) 28 (4):991–995.
   PubMed Web of Science ®Google Scholar
• STOISER B, THALHAMMER F, EL-MENYAWI I et al: Homocysteine and laminine are not prognostic markers in patients with septic inflammatory response syndrome. Clin. Diagn. Lab. Immunol (2000) (1):119–121.
   Google Scholar
• MASSY ZA: Reversal of hyperhomocyst(e)inaemia in chronic renal failure - is folic or folinic acid the answer? Nephrol. Dial. Transplant. (1999) 14 (12):2810–2812.
   Web of Science ®Google Scholar
• GIRGIS S, SUH JR, JOLIVET J, STOVER PJ: 5 -Formyltetrahydrofolate regulates homocysteine remethylation in human neuroblastoma. J. Biol. Chem. (1997) 272(8):4729–4734.
   PubMed Web of Science ®Google Scholar
• WILCKEN DE, DUDMAN NP, TYRRELL PA, ROBERTSON MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism (1988) 37 (7):697–701.
   PubMed Web of Science ®Google Scholar
• JUNGERS P, JOLY D, MASSY Z et al: Sustained reduction of hyperhomocysteinaemia with folic acid supple-mentation in predialysis patients. Nephrol Dial. Transplant. (1999) 1 4 (12) :2903–2906.
   Google Scholar
• BOSTOM AG, SHEMIN D, LAPANE KL et al.: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. (1996) 49 (1) :147–152.
   PubMed Web of Science ®Google Scholar
• ••First randomised controlled study examining the effect ofhigh dose folic acid versus low dose folic acid therapy on tHcy plasma levels in dialysis patients.
   Google Scholar
• MCGREGOR D, SHAND B, LYNN K: A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron (2000) 85(3):215–220.
   PubMedGoogle Scholar
• ARNADOTTIR M, GUDNASON V, HULTBERG B: Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol. Dial. Transplant. (2000) 15(4):524–528.
   PubMed Web of Science ®Google Scholar
• TOUAM M, ZINGRAFF J, JUNGERS P, CHADEFAUX-VEKEMANS B, DReEKE T, MASSY ZA: Effective correc-tion of hyperhomocyst(e)inemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. (1999) 56 (6):2292–2296.
   PubMed Web of Science ®Google Scholar
• BAYES B, BONAL J, PASTOR C, ROMERO R: lipid peroxi-dation in hemodialysis: preventive role of vitamin E and folinic acid. J Am. Soc. Nephrol (1999) 10(9):274A.
   Google Scholar
• BOSTOM AG, SHEMIN D, BAGLEY P et al.: Controlled comparison of L-5 -methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation (2000) 101 (202829–2832.
   Google Scholar
• •This study shows that oral therapy with reduced folates has no better effect on tHcy levels in dialysis patients as compared with folic acid.
   Google Scholar
• TREMBLAY R, BONNARDEAUX A, GEADAH D et al.: Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hy dr o s o luble vitamins. Kidney Int. (2000) 58 (2):851–858.
   PubMed Web of Science ®Google Scholar
• ARNADOTTIR M, BRATTSTROM L, SIMONSEN 0 et al.: The effect of high-dose pyridoxine and folic acid supple-mentation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin. Nephrol (1993) 40 (4):236–240.
   Google Scholar
• ARNADOTTIR M, BERG AL, HEGBRANT J, HULTBERG B: Influence of haemodialysis on plasma total homocys-teine concentration. Nephrol. Dial. Transplant. (1999) 14(1):142–146.
   PubMed Web of Science ®Google Scholar
• HOUSE AA, WELLS GA, DONELLY JG, NADLER SP, HEBERT PC: Randomized trial of high-flux vs. low-flux haemodialysis: effects on homocysteine and lipids. Nephrol. Dial. Transplant. (2000) 15(7):1029–1034.
   PubMed Web of Science ®Google Scholar
• VYCHYTIL A, F0DINGER M, PAPAGIANNOPOULOS M, WOLFL G, HORL WH, SUNDER-PLASSMANN G: Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int. (1999) 55 (5):2054–2061.
   PubMed Web of Science ®Google Scholar
• DE VECCHI AF, CATENA FB, ACCINNI R, PATROSSO C: Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis. Kidney Int. (1999) 56(4):1604–1605.
   PubMed Web of Science ®Google Scholar
• MUDD SH, POOLE JR: Labile methyl balances for normal humans on various dietary regimens. Metabo-lism (1975) 24(6):721–735.
   PubMed Web of Science ®Google Scholar
• JANSSEN MJ, VAN DEN BERG M, VAN GULDENER C, BOERS GH, STEHOUWER CD: Withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin. Nephrol. (1994) 42(2):136–137.
   PubMed Web of Science ®Google Scholar
• WILCKEN DE, GUPTA VJ, BETTS AK: Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin. Sci. (1981) 61 (6):743–749.
   PubMed Web of Science ®Google Scholar
• ARNADOTTIR M, HULTBERG B: Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients. Transplantation (1997) 64 (7):1087.
   PubMed Web of Science ®Google Scholar
• BEAULIEU AJ, GOHH RY, HAN H et al.: Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler. Thromb. Vasc. Biol. (1999) 19 (12):2918–2921.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, SHEMIN D, GOHH RY et al.: Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplanta-tion (2000) 69(102128–2131.
   Google Scholar
• BOSTOM AG, GOHH RY, LIAUGAUDAS G et al.: Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. Atherosclerosis (1999) 145 (1) :221–224.
   PubMed Web of Science ®Google Scholar
• SUNDER-PLASSMANN G, FODINGER M, GOHH RY, SELHUB J, BOSTOM AG: Cyclosporine use is not independently associated with increased plasma tHcy levels in Austrian or United States chronic renal transplant recipients. J. Am. Soc. Nephrol. (2000) 11 (9):726A.
   Google Scholar
• FERNANDEZ-MIRANDA C, GOMEZ P, DIAZ-RUBIO P et al.: Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin. Transplant. (2000) 14 (2):110–114.
   PubMed Web of Science ®Google Scholar
• IGNATESCU M, FODINGER M, KLETZMAYR J, BIEGLMAYER C, HORL WH, SUNDER-PLASSMANN G: The role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells. Kidney Int. (2001). (In Press).
   Google Scholar
• VAN GULDENER C, JANSSEN MJFM, LAMBERT J et al.: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocystein-aemia in haemodialysis patients. Nephrol. Dial. Transplant. (1998) 13(0:106–112.
   PubMedGoogle Scholar
• VAN GULDENER C, JANSSEN MJ, LAMBERT J, TER WEE PM, DONKER AJ, STEHOUWER CD: Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Pent. Dial. Int. (1998) 13(3):282–289.
   Google Scholar
• KUNZ K, PETITJEAN P, LISRI M et al.: Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol. Dial. Transplant. (1999) 14(8):1934–1942.
   Web of Science ®Google Scholar
• THAMBYRAJAH J, LANDRAY MJ, MCGLYNN FJ, JONES HJ, WHEELER DC, TOWNEND JN: Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation (2000) 102(8) :871–875.
   PubMed Web of Science ®Google Scholar
• GENEST JJ, AUDELIN MC, LONN E: Homocysteine: to screen and treat or to wait and see? CMAJ (2000) 163 (1):37–38.
   PubMed Web of Science ®Google Scholar